Reduction in Postprandial Peak Glucose With Increased Technosphere Insulin Dosage.

inhaled insulin pharmacokinetics postprandial glucose type 1 diabetes type 2 diabetes

Journal

Journal of diabetes science and technology
ISSN: 1932-2968
Titre abrégé: J Diabetes Sci Technol
Pays: United States
ID NLM: 101306166

Informations de publication

Date de publication:
14 Jul 2022
Historique:
entrez: 14 7 2022
pubmed: 15 7 2022
medline: 15 7 2022
Statut: aheadofprint

Résumé

Technosphere Insulin (TI) is an ultra-rapid-acting inhaled insulin. This study assessed the mean peak two-hour postprandial glucose concentration with the initial TI dose (dose 1) calculated per the current label (United State Prescribing Information) compared with a ~2× higher dose (dose 2). Secondary objectives were to evaluate hypoglycemia within the two-hour postprandial period, evaluate change in forced expiratory volume in one second (FEV Twenty patients with diabetes, on basal-bolus insulin therapy, received an initial dose 1 of TI followed by the higher dose 2, one to three days later. Subjects received an identical meal for both visits, and TI doses were administered immediately prior to the meal. The higher dose 2 provided significant reductions in mean postprandial glucose excursion (PPGE) in the two-hour postprandial period starting from 45 minutes ( The higher dose 2 reduced PPGE versus the current label recommended dose 1 within the two-hour postprandial timeframe without any new safety concerns. When confirmed with a larger study, this higher TI dosing recommendation may help patients and clinicians minimize immediate postprandial hyperglycemia when titrating TI for prandial glucose control.

Sections du résumé

BACKGROUND UNASSIGNED
Technosphere Insulin (TI) is an ultra-rapid-acting inhaled insulin. This study assessed the mean peak two-hour postprandial glucose concentration with the initial TI dose (dose 1) calculated per the current label (United State Prescribing Information) compared with a ~2× higher dose (dose 2). Secondary objectives were to evaluate hypoglycemia within the two-hour postprandial period, evaluate change in forced expiratory volume in one second (FEV
METHODS UNASSIGNED
Twenty patients with diabetes, on basal-bolus insulin therapy, received an initial dose 1 of TI followed by the higher dose 2, one to three days later. Subjects received an identical meal for both visits, and TI doses were administered immediately prior to the meal.
RESULTS UNASSIGNED
The higher dose 2 provided significant reductions in mean postprandial glucose excursion (PPGE) in the two-hour postprandial period starting from 45 minutes (
CONCLUSIONS UNASSIGNED
The higher dose 2 reduced PPGE versus the current label recommended dose 1 within the two-hour postprandial timeframe without any new safety concerns. When confirmed with a larger study, this higher TI dosing recommendation may help patients and clinicians minimize immediate postprandial hyperglycemia when titrating TI for prandial glucose control.

Identifiants

pubmed: 35833638
doi: 10.1177/19322968221110622
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

19322968221110622

Auteurs

Kevin B Kaiserman (KB)

MannKind Corporation, Westlake Village, CA, USA.

Mark Christiansen (M)

Diablo Clinical Research Inc., Walnut Creek, CA, USA.

Sunil Bhavsar (S)

MannKind Corporation, Westlake Village, CA, USA.

Johanna Ulloa (J)

MannKind Corporation, Westlake Village, CA, USA.

Brandi Santogatta (B)

MannKind Corporation, Westlake Village, CA, USA.

Joseph Hanna (J)

MannKind Corporation, Westlake Village, CA, USA.

Timothy S Bailey (TS)

AMCR Institute, Escondido, CA, USA.

Classifications MeSH